Who is sponsoring NCT03526666?

NCT03526666 is sponsored by Van Andel Research Institute.

What drugs are being tested in NCT03526666?

Interventions in NCT03526666: Peripheral blood collection.

What condition does NCT03526666 study?

NCT03526666 studies Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS, AML, CMML.

Is NCT03526666 still recruiting?

NCT03526666 is currently completed. Last updated 3 October 2019.

Last reviewed 2019-10-03 · How we verify

NCT03526666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Completed Last updated 3 October 2019

What this trial tests

trial testing Peripheral blood collection in Myelodysplastic Syndromes in 50 participants. Completed in 31 October 2018.

Timeline

1 November 2017

Primary endpoint
31 October 2018

31 October 2018

Quick facts

Lead sponsor	Van Andel Research Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 November 2017
Primary completion	31 October 2018
Estimated completion	31 October 2018
Sites	2 locations across United States

Drugs / interventions tested

Peripheral blood collection

Conditions studied

Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Chronic Myelomonocytic Leukemia — all drugs for Chronic Myelomonocytic Leukemia →
MDS — all drugs for MDS →

Sponsor

Van Andel Research Institute

Who can join

18 and older, any sex, with Myelodysplastic Syndromes or Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy.
Isola S, Gammeri L, Furci F, Gangemi S, et al · · 2024 · cited 15× · PMID 39000393 · DOI 10.3390/ijms25137284
Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions.
Capelletti MM, Montini O, Ruini E, Tettamanti S, et al · · 2024 · cited 2× · PMID 39795903 · DOI 10.3390/ijms26010045
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x

Verify or expand the search:

Other trials of Peripheral blood collection

Trials testing the same drug.

NCT06281262 — Selected Immunological Indicators and Microbiota in Patients With Premature Birth and Preeclampsia · unknown
NCT04477512 — Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CA · Phase 1 · completed
NCT03970434 — Drug Concentration of Metformin According to Sampling Method · Phase 1 · completed
NCT02801942 — Immune Profile in Subjects With New Onset Type 1 Diabetes · NA · completed

Other recruiting trials for Myelodysplastic Syndromes

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting

Other Van Andel Research Institute trials

Trials by the same sponsor.

NCT04143152 — Pancreatic Cancer Biomarker Study · active not recruiting
NCT04159207 — A Longitudinal Study of Inflammatory Pathways in Depression · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03526666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Van Andel Research Institute
Last refreshed: 3 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing